Want to join the conversation?
Drugmaker $VRTX reported a narrower 2Q16 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $64.53MM or $0.26 per share from $188.85MM or $0.78 per share last year. Revenue grew to $431.61MM from $166.08MM. Non-GAAP EPS was $0.24 compared to loss of $0.54 per share a year ago.
The latest earnings report by $VZ shows how it is losing customers despite offering the unlimited data plans, a record for the company.
$BEBE is closing down all its stores by the end of May.
$WFC agreed to hike its payout in a class-action settlement over unauthorized accounts by $32 million to $142 million for its retail sales practices. The settlement will now include customers who were impacted as early as May 2002.